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Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from
one signaling motif to another as a result of cancer progression and/or drug intervention.
This resistance is one of the key determinants of efficacy in targeted anti-cancer drug
therapy. Although poorly understood, drug resistance is already being addressed in combi-
nation therapy by selecting drug targets where SN sensitivity increases due to combination
components or as a result of de novo or acquired mutations. Additionally, successive drug
combinations have shown low resistance potential.To promote a rational, systematic devel-
opment of combination therapies, it is necessary to establish the underlying mechanisms
that drive the advantages of combination therapies, and design methods to determine drug
targets for combination regimens. Based on a joint systems analysis of cellular SN response
and its sensitivity to drug action and oncogenic mutations, we describe an in silico method
to analyze the targets of drug combinations. Our method explores mechanisms of sensi-
tizing the SN through a combination of two drugs targeting vertical signaling pathways.
We propose a paradigm of SN response customization by one drug to both maximize
the effect of another drug in combination and promote a robust therapeutic response
against oncogenic mutations. The method was applied to customize the response of the
ErbB/PI3K/PTEN/AKT pathway by combination of drugs targeting HER2 receptors and pro-
teins in the down-stream pathway. The results of a computational experiment showed
that the modification of the SN response from hyperbolic to smooth sigmoid response
by manipulation of two drugs in combination leads to greater robustness in therapeutic
response against oncogenic mutations determining cancer heterogeneity. The application
of this method in drug combination co-development suggests a combined evaluation of
inhibition effects together with the capability of drug combinations to suppress resistance
mechanisms before they become clinically manifest.
Keywords: anti-cancer combination therapy, cancer drug resistance, pathway engineering, signaling networks,
pertuzumab, PI3K/PTEN/AKT
INTRODUCTION
Anti-cancer combination therapies are an increasingly promising
way to better treat patients, offering an increase in efficacy of drugs,
and a means to overcome/avoid resistance to targeted drug therapy.
An evidence base of successes of multidrug strategies in anti-cancer
therapy is growing yearly, but typically the mechanism of synergy
is not entirely understood. To promote a more directed and sys-
tematic development of combination therapies, it is necessary to
clearly elucidate the underlying mechanisms that drive the advan-
tages of drug combination effect. Exploration of these mechanisms
can impact significantly on the determination and validation
of advanced combination of targets in novel drug development
strategies such as drug combination co-development (1) and drug-
diagnostics co-development (2). With respect to a drug combina-
tion co-development strategy, novel compounds should be devel-
oped in a combinatorial context and not independently in order
to gain those proven integrative benefits with respect to tumor
growth inhibition, drug resistance, and toxicity. In the drug–
diagnostic co-development model, the drug and the diagnostic
assay are developed in conjunction. Companion diagnostic (CDx)
assays as well as clinical trial strategies in the case of drug com-
bination therapy should be adapted to multiple biomarkers and
different drug combinations (2). Considering the risk of increasing
toxicity by the use of drug combination therapy, the US food and
drug administration (FDA) released drug co-development guid-
ance, which proposed stringent regulatory recommendations for
the use of combination strategies (1, 3). According to these rec-
ommendations, there should exist a strong biological rationale for
the use of the combinations and proven significant advantages
over the use of the drugs as individual agents.
Rational determination and validation of advanced targets
for drug combination therapy are the main challenges for these
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strategies. The inherent complexities of signaling networks (SNs),
including crosstalk logic and redundancy in their topology (4,
5) limit the relevance of genotype-based screening to identify
and validate optimal drug combination targets among several
hundred possible targets. In the face of these challenges, we
need more sophisticated methods to design effective combination
therapies (1).
Systems biology and computational bioinformatics may offer
a key role in advancing drug combination co-development. These
technologies are being developed to support rationalized screening
of effective drug combinations, and to formulate quantitative cri-
teria for drug combination target validation and specific properties
of each drug in a combination context and in the face of different
mutational statuses of different cancers (6–9). Such developments
are motivated by the potential to reduce the size, duration, and
cost of clinical trials as well as to accelerate regulatory approval.
Our own studies to support drug combination co-development are
described here. Our method is based on analysis of the response
of a cellular SN to drug intervention, and its modification by drug
combination to achieve high efficacy and reduce drug resistance
potential. The approach developed here is founded on the two
most attractive advantages of drug combination well established
recently: (i) a drug combination suppresses de novo or acquired
resistance to one of the drugs in the combination – a resistance
suppression effect; and (ii) one drug in a combination sensitizes
therapeutic response to a second drug – a sensitizing effect.
Resistance suppression effects arising from drug combination
are used widely in clinics now, by manipulating pathway dynam-
ics or by slowing down the cancer evolution. Some examples of
pathway manipulations are summarized in Ref. (1) targeting dif-
ferent domains of the same protein with two drugs [for example,
trastuzumab combined with pertuzumab for human epidermal
growth factor receptor, HER2, in breast (10) and ovarian (11, 12)
cancers]; horizontally targeting parallel signaling pathways [for
example, combined MEK and PI3K/AKT inhibition (13, 14)], and
vertically targeting up- and down-stream pathways in one SN [for
example, targeting BRAF and MEK, HER2, and PI3K, PI3K/AKT
and mTOR (15–17)]. An evolutionary approach (adaptive ther-
apy) to treat drug resistance has been suggested, with the aim
of lowering the cancer cell’s capacity to evolve resistance mecha-
nisms through adaptive combination therapy in order to hinder
the emergence of resistance types (18). Beyond these approaches,
the combination of chemotherapy and molecular targeted ther-
apy demonstrates a complementary mechanism of efficacy and
may suggest a route for next-generation cancer therapy (10, 19,
20). For example, a clinical trial of HER2-positive breast can-
cer progression following HER2 inhibitor trastuzumab therapy
showed that trastuzumab in combination with chemotherapeutic
agent (capecitabine) was more effective than capecitabine alone.
It would seem that trastuzumab sensitizes cell response to other
drugs despite the fact that cells are refractory to trastuzumab and
that there is therapeutic benefit to continue trastuzumab therapy
in combination with other drugs beyond progression (21).
The sensitizing effects of drug combinations are well estab-
lished in combined therapies targeting different pathways, such
as the PI3K/PTEN/AKT and MAPK networks (13, 14); EGFR,
DNA-damaging apoptotic signaling pathways (22) as well as in
drug combinations inhibiting different nodes in the same path-
way: PI3K/PTEN/AKT/mTOR (23–25), Ras/RAF/MEK/ERK (26,
27). However, there are longer-term implications arising from
drug combinations since they may lead to different mutations
and negatively impact resistance potential. For example, compar-
ison of pre- and post-trastuzumab treatment of tissue samples
in metastatic HER2-amplified breast cancer from patients pro-
gressing on trastuzumab allowed determination of mutations
in PIK3CA and PTEN arising during treatment (4). A signifi-
cant reduction, or full loss, of PTEN expression was observed in
trastuzumab refractory metastatic tumors compared to the cohort
untreated by trastuzumab. It was suggested that PTEN expression
reduction was acquired as a result of trastuzumab therapy, lead-
ing itself to trastuzumab resistance (4). In contrast, treatment by
everolimus, an mTOR inhibitor, did not increase mutational load
in pre/post treatment samples of renal carcinomas (28). More-
over, this phenomenon is context specific: for example, abiraterone
alone and given in combination with other drugs to control side
effects contributes to resistance by activating mutations in the hor-
mone receptor genes; however, a different combination including
abiraterone was reported to delay drug resistance (29).
These examples highlight the complexities of combination
drug therapy design, including the change in sensitivity to muta-
tion and resistance potential through combination action, and
the attending challenges associated with validation. To help over-
come these complexities and challenges, we propose a method
for the in vitro/in vivo/in silico validation of the targets of drug
combinations and quantitative estimation of the perturbations
induced by drugs in SNs. Our method is based on the study of
drug response characteristics of (i) a SN and its modification by
different oncogenic mutations and drug action; and (ii) pertur-
bation of SN sensitivity to drug action induced by mutations.
Using sensitivity analysis (SA) of this signaling response, we show
that inhibition of various targets by the first drug significantly
sensitizes SN response to both compensating mutations leading
to resistance and the second drug in combination. We present
a scheme for customizing the SN response through drug com-
bination to enhance the robustness of the therapeutic response
due to weakening of the drug-sensitizing effect to compensation
mutations. To demonstrate the method and to study in detail the
drug/mutation modification of SN response, we used the kinetic
model of drug combination targeting HER2 receptors and vertical
PI3K/PTEN/AKT signaling pathway (30–32).
MATERIALS AND METHODS
The method is based on the analysis of input/output (I/O)
responses of a cellular SN, RSN=Cout (C in, PSN, D, t ), which
describes the relation between output signal Cout and input signal
C in (see scheme in Figure 1). RSN depends on molecular parame-
ters, PSN, of the SN components: specifically, kinetic parameters
of the proteins/receptors, K = k1, . . ., kn (dissociation constants,
catalytic rates), and their expression levels,E = e1, . . ., em.RSN also
depends on the concentrations of drugs,D, which inhibit proteins
in the SN. Typically, RSN is measured in experimental systems
as the dose dependence of output signal on drug/ligand concen-
tration at a defined time, t, following ligand/drug application in
a cellular assay. The experimental dose dependence, RSN=Cout
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FIGURE 1 | Scheme of the method of customizing cellular signaling
response by drug combination targeting upstream (drug D1) and
down-stream pathway (drug D2). Plot sketches A, B, and C show
responses, RUSP =Cout,USP (C in,USP, D1), RDSP =Cout,DSP (C in,DSP, D2), and the
whole SN RSN =Cout (C in, D1, D2), respectively. Examples of the responses
of unmodified DSP (black line), modified by a mutation in the DSP (red lines)
and modified by the second drug D2 (blue lines) in the presence of the
mutation. Input signal C in inhibited by drug D1 is shown by the dashed lines.
(C in, PSN, D, t ), on drug concentration allows the definition of
the IC50 of drug D1, which strongly depends on the target of drug
D2, the concentration of this second drug, and the mutational
status of the SN determined by parameters, PSN.
To analyze in detail the combination effect of two drugs at
different mutations of the SN, we decompose the SN into up-
and down-stream pathways that are the targets of drugs D1 and
D2, respectively (see Figure 1). The response, RSN, of the SN can
be represented through the response RUSP of upstream pathway
(USP) and the response, RDSP of down-stream pathway (DSP) in
the form, RSN=RDSP(RUSP), where RUSP=Cout,UPS(C in,PUSP,
D1, t ) and RDSP=Cout,DSP(C in,DSP,PDSP, D2, t ). In this for-
mulation, we took into account equivalences of I/O signals:
C in,DSP=Cout,USP and Cout_DSP=Cout (see Figure 1). Theoreti-
cally, the I/O responses,RSN,RUSP, andRDSP, are readily calculated
from the model of the SN. Experimentally, RDSP can be extracted
from two experimental dose dependencies: dose dependence of the
whole SN,RSN, and the receptor activation/inhibition dose depen-
dence on activator/inhibitor concentration,RUSP, and represented
in the form RDSP=Cout(RUSP,PDSP,D2,t ).
Input/output response RDSP determines the output signal
amplitude of the DSP depending on input signals, which is con-
trolled by the first drug D1, the molecular parameters, PDSP, and
the action of the second drug D2. Analysis of RDSP allows us to
study the effect of mutations, i.e., changes in kinetic properties and
expression levels of proteins,PDSP, on the change inRDSP and how
these changes determine a transition from drug sensitivity to drug
resistance. Plots A, B, and C (black lines) in Figure 1 show arbi-
trary responses,RUSP,RDSP, and RSN, corresponding to sensitivity
of the SN toD1. According to this type of smooth hyperbolicRDSP,
the output signal of the SN changes when the input signal changes
under inhibitor D1 (see black points in plots A, B, and C show-
ing inhibited signal at drug concentration D1 in Figure 1). The
example of I/O response RDSP modified by oncogenic mutations
is shown in plot B in Figure 1 (red line). This type of switch-like
RDSP corresponds to resistance of the SN to drug D1 because the
output signal of the SN does not change when the input signal
changes under the action of inhibitor D1 (see red lines and points
in plots B and C in Figure 1). Our method provides a means to
search for the protein target for drug D2 to modify the response,
RDSP, in such a way as to reach two complementary effects: first,
an increase in inhibition effectiveness of drug D1 (see, e.g., RDSP
modified by drug D2 in plot B, blue line in Figure 1); and sec-
ond, to ensure robustness of this inhibition effect against different
mutations in DSP (see below). One example of such a modified
RDSP is shown by the blue line in plot B in Figure 1.
To evaluate the robustness of the response RDSP, we supple-
mented the analysis of the shape of the response curve with the
SA of the DSP to both external and internal perturbations: i.e.,
changes in input signal and alterations of kinetic parameters and
expression level of the proteins involved, PDSP. We define the rel-
ative sensitivity, SDSP, of the DSP to the input signal as the relative
change of output signal Cout,DSP in response to a relative change
in input signal C in,DSP, which can be written through changes in
I/O responses, RUSP and RDPS:
SDSP(Cin,DSP, PDSP,D2, t ) = ∆Cout,DSP
∆Cin,DSP
= ∆RDSP/RDSP
∆RUSP/RUSP
. (1)
To analyze the sensitivity of the DSP response to different muta-
tions causing changes in protein parameters (phosphorylation rate
and expression level), we calculate an absolute value of relative
sensitivity to changes in individual parameters p of proteins:
SDSP,p(Cin,DSP, PDSP,D2, t ) =
∣∣∣∣∆RDSP/RDSP∆p/p
∣∣∣∣ . (2)
We base our local SA on the results of the application of SA to
a study of the responses of various cellular signaling pathways to
different mutations and drug actions. For the first time, the com-
putational analysis of the change in sensitivity of SN depending on
the protein expression level was carried out in the modeling of the
apoptosis pathway (33). The SA revealed a sensitivity increase in
the response of the apoptotic pathway to overexpression of Bcl-2
protein. It allowed prediction of selectivity of a Bcl-2 inhibitor for
tumor cells with Bcl-2 overexpression against healthy cells with a
normal level of Bcl-2. SA was first used to analyze the robustness
of the MAPK cascade to oncogenic mutations in Ref. (34). The
further application of the SA to an in silico study of the effects
of the most frequent mutations in cancer (EGFR, Ras, BRaf) on
the dynamics of MAPK response to receptors activation were ana-
lyzed in Refs. (35–39). An application of the SA to a study of SN
response to drug action was first studied in Refs. (40, 41).
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Sensitivity analysis of the I/O response allows us to: (i) deter-
mine the resistance potential of a single drug and drug combina-
tion to protein mutations in the DSP; and (ii) determine whether
the DSP response to a specific drug combination is robust against
various mutations in the DSP and suggest more robust com-
binations, which enhance the therapeutic effect in the face of
mutations.
RESULTS
CHARACTERIZING SIGNALING NETWORK RESPONSE TO DIFFERENT
ONCOGENIC MUTATIONS
We illustrate this method by application to the analysis of the
response of PI3K/PTEN/AKT signaling to a drug combination tar-
geting the HER2 receptor and a protein in the DSP, PI3K, which
were established to be promising drug targets in both mono- and
combination therapy in different cancers (1, 15, 42). The aim of the
analysis of known drugs and targets is to elucidate the mechanism
underlying high efficacy of their combination against different
oncogenic mutations in cancer (43, 44).
The analysis is based on the kinetic model of Ras/RAF/MEK/ERK
and PI3K/PTEN/AKT signaling developed in Ref. (30). This model
describes the response kinetics of the SN to heregulin (HRG)-
induced HER3/HER2 receptor heterodimerization and the effect
of HER2 inhibitor, pertuzumab (2C4 antibody), on ERK and AKT
activation in the human ovarian carcinoma cell line PE04. The
scheme of the PI3K/PTEN/AKT SN that corresponds to the SN
undertaken here is shown in Figure 2. The ordinary differential
equations (ODEs) of the model and set of the model parameters
are given in the Supplementary Information. In the model, we
neglected other ErbB receptor heterodimers because HER2/HER3
heterodimerization activation was found to be the most mitogenic
signal and induces cellular growth in the PE04 cell line (45). The
model of the SN including 56 ODEs, 58 reactions, and almost
100 parameters (kinetic constants and protein concentrations)
was parameterized by experimental data on the phosphorylation
kinetics of HER2, ERK, AKT, and PTEN in the absence and pres-
ence of pertuzumab (30). Considering incomplete identifiability
of model parameters based on the limited set of experimental data
used in model calibration, we validated the model on independent
experimental data on the different combination effects of PTEN,
PI3K, and HER2 inhibition on the ErbB/PI3K/PTEN/AKT path-
way activation (30, 32, 40, 41, 46). Model validation evidenced a
good account of sensitivity of the SN to single drug action (per-
tuzumab) and drug combinations targeting different nodes of the
SN (pertuzumab and inhibitors of PI3K, PDK1, and PTEN) (32,
40, 41, 46).
According to our method, we decomposed the ErbB/PI3K/
PTEN/AKT network into two sub-networks: an upstream sig-
naling system – the receptor system constituting HER2/HER3
receptor signaling (USP); and a down-stream pathway consti-
tuting PI3K/PTEN/AKT pathway (DSP). We used the phospho-
heterodimer HER23 signal (pHER23) as the output signal
of USP and input signal of the DSP (see Figure 2). The
I/O response, RUSP, of USP was defined as the dependence
of pHER23 concentration on the concentration of HER2
inhibitor, 2C4: RHER= pHER23(HRG, PUSP, 2C4, t ). The I/O
response of DSP, RAKT, is the dependence of pAKT on
FIGURE 2 | Scheme of PI3K/PTEN/AKT signaling network activated by
heterodimerization of HER2/HER3 receptors induced by heregulin
(HRG) and inhibited by pertuzumab, 2C4. Decomposition of the signaling
network to upstream pathway (receptor signaling pathway) and
down-stream pathway (PI3K/PTEN/AKT network) is shown.
concentration of phospho-heterodimer HER3/HER2, pHER23:
RAKT= pAKT(pHER23, PAKT, D2, t ). The input signal of
PI3K/PTEN/AKT is the receptor phosphorylation signal,pHER23,
which is changed in the calculation by varying the concentrations
of the HER2 inhibitor, 2C4, in the physiological region from zero
to saturated value, 1µM (47). The dose dependence, RAKT, was
calculated at time t = 30 min after HRG and 2C4 addition that
corresponds to saturation of pHER23 and pAKT signals both in
modeling and experiment (30, 32).
To show how the I/O response RAKT depends on mutations
in the PI3K/PTEN/AKT pathway, we compared the theoretical
response, RAKT= pAKT(pHER23, PAKT, D2, t ) for the unper-
turbed DSP (see black line in Figure 3A) with the response
RAKT modified by oncogenic mutations in the PI3K/PTEN/AKT
pathway: PTEN loss (50 and 70%), variation of PI3K activity
(Figure 3B), and 50% overexpression of AKT (see red lines in
Figures 3A–C).
Comparing the shapes of unmodified and modified responses
curvesRAKT, we defined sensitive and resistance modes in the DSP.
In sensitive mode, an increase in pHER23 signal causes a gradual
increase in pAKT signal from 0 to its saturated value (black line in
Figure 3A). In resistance mode, the RAKT curve becomes steeper
and transforms to a switch-like response curve at the activation
mutations (red lines in Figures 3A,B). The pAKT output signal is
unresponsive to input pHER23 signal controlled byD1: e.g.,pAKT
signal does not change when pHER23 changes in the range from
0.04 to 1 at 70% PTEN loss and activated mutation in PI3K (see red
lines 3 and 4 in Figures 3A,B, respectively). In the case of AKT over-
expression, pAKT signal significantly exceeds the basal activation
level of pAKT in the range of pHER23 signal from 0.04 to 1 (see
red line in Figure 3C). This lack of AKT response to input signal at
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FIGURE 3 | Input/output response of the PI3K/PTEN/AKT pathway RAKT
to pHER23 input signal and its modification by activation mutations of
PTEN, PI3K, and AKT proteins and inhibition of PI3K by LY294002
inhibitor. (A) Modification of RAKT by a change of initial concentration of
PTEN: response curve at the reference concentration of PTEN0 =40µM (line
1), 50% PTEN loss (line 2), 70% PTEN loss (line 3). Modification of RAKT by
PI3K inhibition: 0.3µM LY294002 (line 4), 0.5µM LY294002 (line 5), and 1µM
LY294002 (line 6). Modification of RAKT by 50% PTEN loss and inhibition of
PI3K by 3µM LY294002 (line 7). Points a, b, c, d, and e correspond to
saturated pAKT signal (pHER23=1), its inhibition by 100 nM 2C4
(pHER23=0.1), resistance to 2C4 at 50% PTEN loss (pHER23= 0.1),
combined inhibition by 2C4 and LY294002 in the absence and presence of
50% PTEN loss (pHER23=0.1), respectively. (B) Modification of RAKT by a
change of PI3K activities, kPI3K: reference kPI3K,0 (line 1), 0.5 kPI3K,0 (line 2), 0.3
kPI3K,0 (line 3), and 0.1 kPI3K,0 (line 4). (C) Modification of RAKT by 50%
overexpression of AKT: reference concentration AKT0 (line 1) and 1.5 AKT0
(line 2). Modification of RAKT by 1µM LY294002 at reference concentration of
AKT0 (line 3) and 50% overexpression of AKT (line 4).
pathway modification by mutations corresponds to the resistance
of pAKT signal to HER2 inhibition by pertuzumab. Amongst the
modifications of response RAKT shown in Figures 3A–C, the most
pronounced transition from a graded to a steep switch-like shape
was observed at PTEN loss. In the model, this effect is due to
the post-translational regulation of PTEN activity by its phospho-
rylation (see Figure 2) leading to the additional loss of PTEN
activity (31, 48).
Analysis of RAKT shows how receptor inhibition of pHER23
signal by D1 transforms the functioning state of the DSP from
its normal function at saturated receptor signal (pHER23= 1) to
non-saturated inhibited signal at low pHER23 <0.3 (points a and
b in Figure 3A, respectively). When the DSP functions in non-
saturation mode, the inhibited input signal differs from that in
(normal) saturation mode in both a decrease in pAKT signal and
an increase in sensitivity of the DSP to both input signal pHER23
and mutations causing changes in kinetic parameters and expres-
sion level of the proteins involved. To study the second effect,
we analyzed the behavior of sensitivities of the DSP SDSP Eq. 1
and SDSP,p Eq. 2 at different internal (mutations) and external
(inhibition) modifications of the DSP.
The relative sensitivity of the PI3K/PTEN/AKT pathway is
defined as the relative response (change) of the output signal of
DSP,∆pAKT, to a relative change in its input signal,∆pHER23:
SAKT(pHER23, PAKT,D2, t ) = ∆pAKT/pAKT
∆pHER23/pHER23
. (3)
Sensitivity SAKT (Eq. 3) was calculated at time t = 30 min after
HRG and 2C4 addition that corresponds to the saturation of both
pHER23 and pAKT signals. Information on SAKT can be obtained
based on an analysis of the tangent of the response curve RAKT:
the steeper the response behaviors, the more sensitive the system
responses to the external signal. Commonly, sensitivity increases
at low input signal and this corresponds in our case to recep-
tor signal inhibition by the first drug (see Figure 3A). At high
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receptor signal, SAKT decreases at saturated signal, pHER23∼= 1.
We represent the theoretical sensitivity SAKT (Eq. 3) as the upper
heatmap in Figure 4 (columns 1–4) calculated at different pertur-
bations of the DSP: (1) at the activation of DSP (pHER23= 1);
(2) at the presence of 100 nM 2C4 (pHER23= 0.1); (3) 50%
PTEN loss (pHER23= 1); and (4) 50% PTEN loss with 100 nM
2C4 (pHER23= 0.1). According to the shape change in response
curve under these perturbations (see Figure 3A), the sensitivity
SAKT increases under 2C4 treatment in sensitive mode (compare
columns 1 and 2) and decreases at 50% PTEN loss, corresponding
to resistance mode (compare columns 1 with 3 and 4).
We also observed that the sensitivity of the DSP SAKT,p to pro-
tein parameters and expression level increases in the same region
of pHER23 signal (40). Relative sensitivities SAKT,p (Eq. 2) of the
PI3K/PTEN/AKT pathway to a specific parameter p (including
kinetic parameters and expression levels of the signaling proteins)
were determined as follows:
SAKT,p(pHER23, PAKT,D2, t ) =
∣∣∣∣∆pAKT/pAKT∆p/p
∣∣∣∣ . (4)
To show how drug and protein mutations change sensitivity,
SAKT,p (Eq. 4), we calculated and compared SAKT,p for kinetic
parameters and initial concentrations of proteins involved in the
PI3K/PTEN/AKT network under a normal functioning of the
DPS and the mutations considered above. Figure 4 (middle and
lower heatmaps, columns 1–4) shows SSTS,p calculated at: (1)
HER23 activation by HRG (pHER23= 1); (2) in the presence
of HER2 inhibitor, 2C4, when pHER23 signal is 90% inhibited
(pHER23= 0.1); (3) at 50% PTEN loss (pHER23= 1); and (4)
at 50% PTEN loss in the presence of 2C4 (pHER23= 0.1) (see
columns 1–4 in Figure 4, respectively). Analysis of SAKT,p at nor-
mal signaling in the PI3K/PTEN/AKT network (pHER23= 1)
revealed the most sensitive modules within this network (see col-
umn 1 in Figure 4). The results obtained in our model are in
agreement with the results of local and global sensitivity analyses
of other models of the PI3K/PTEN/AKT pathway (41, 49, 50).
We observed a two-to-four orders of magnitude increase in
SAKT,p in response to changes in the kinetic parameters and initial
concentrations of the proteins at 90% inhibition of pHER23 sig-
nal by 100 nM 2C4 (compare columns 1 and 2 in Figure 4, lower
heatmap). This increase correlates with an increase in sensitiv-
ity, SAKT, at an inhibited signal of pHER23 (see upper heatmap
in Figure 4). The increase in sensitivities SAKT and SSTS,p at low
pHER23 signals corresponds to the transition of the DSP from
functioning in saturated mode (pHER23∼= 1) to functioning at
HER2 inhibition (non-saturation). This correlation in the behav-
ior of SAKT and SSTS,p can be readily understood: sensitivity,
SAKT,p(pHER23, PAKT), to a change in PAKT varies in accordance
with sensitivity SAKT (pHER2, PAKT) to a change in input signal,
pHER23:
∆SAKT(pHER23, PAKT)
∆p
= ∆SAKT,p(pHER23, PAKT)
∆pHER23
, (5)
where∆SAKT and∆SAKT,p denote sensitivity changes. Equation 5
can be derived from well-known equality of mixed derivatives
FIGURE 4 | A change in sensitivities SAKT and SAKT,p following different
perturbations in the PI3K/PTEN/AKT network. Heatmap of sensitivity SAKT
to pHER23 signal (upper heatmap) and sensitivity SAKT,p to kinetic parameters
(middle heatmap) and initial protein concentrations (lower heatmap) at normal
functioning of the SN (column 1), in the presence of 100 nM 2C4 (column 2),
and at 50% PTEN loss in the absence (column 3) and presence of 100 nM
2C4 (column 4). Columns 5–8 show SATP,p as per columns 1–4 in the presence
of 3µM LY294002. The relative change of the parameters in sensitivity
analysis was 0.01% (see Eq. 4) and sensitivity values were taken at time
t =30 min after HRG and 2C4 addition.
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for continuous function of many variables, turning to infinitesi-
mal increments ∆ in Eq. 5 – in our case for I/O response function
pAKT(pHER23,PAKT) depending on variables pHER23 and PAKT
taken at fixed time t.
We applied the results of this analysis to study the change in SN
sensitivity to oncogenic mutations in the PI3K/PTEN/AKT path-
way. Given an increase in sensitivity SAKT,p to all the parameters
and expression levels of the proteins of the DSP to external per-
turbation (+2C4) (see column 2 in Figure 4, lower heatmap),
we calculated sensitivity SAKT,p at internal perturbations: 50%
PTEN loss (column 3 in Figure 4, lower heatmap), variation of
PI3K catalytic rate, and 50% overexpression of AKT (data not
shown). For all perturbations, we observed the same dramatic fall
in sensitivity, SSTS,p, over almost all parameters and this drop in
SSTS,p endows the DSP with insensitivity to any further changes
in kinetic parameters of proteins and their abundances. The fall
of SSTS,p correlates with the shape change of the response curve
pAKT(pHER23, PAKT) (red lines in Figure 3) and the loss of sen-
sitivity SAKT to input receptor signal pHER23 inhibited by 2C4.
In contrast to a sensitive network, this insensitive DSP cannot be
sensitized by drug D1 inhibiting the input signal: the calculation
of SAKT,p at 100 nM 2C4 showed no change in sensitivity follow-
ing 50% PTEN loss (see column 4, lower heatmap in Figure 4).
Thus, drug D1 (2C4) acts in very different ways on unmodified
and modified DSPs: it sensitizes the unmodified network (sensi-
tive mode), but does not change sensitivity and inhibition level in
the mutated DSP. Further D1, inhibiting the input signal, shifts the
DSP to a state with more sensitivity to compensation mutations,
which may in turn cause the restoration of the initially activated
signal and also lower network sensitivities to other external and
internal perturbations.
CUSTOMIZING SIGNALING NETWORK RESPONSE THROUGH DRUG
COMBINATION
Our analysis of the sensitivity of the PI3K/PTEN/AKT pathway
showed that inhibition of input signal pHER23 sensitizes the
response of the DSP to protein perturbations such as a change
in protein expression level. Such perturbations can be also exerted
by inhibition of protein phosphorylation activity. Here, we use the
observed drug-induced sensitizing effect to enhance the action
of the second drug D2 targeting the DSP. Specifically, we con-
sidered PI3K inhibition by LY294002 and calculated the response
of PI3K/PTEN/AKT pathway, RAKT= pAKT(pHER23, PAKT, D2,
t ) to pHER23 signal at different concentrations of this inhibitor.
Inhibition of PI3K modifies the response curve from hyperbolic
to a smooth sigmoid form with high inhibition effect (see blue
lines in Figures 3A,C). This modified response has a most pro-
nounced inhibition effect of the second drug D2 in the region of
low pHER23 signal (0–0.2) where the sensitizing effect of drug
D1 is maximal (see black lines in Figures 3A,C and column 2 in
Figure 4). This observation confirms that the effective and syner-
gistic effect of the HER2 inhibitor (D1) in combination with PI3K
inhibitor (D2) is due to a sensitizing effect of D1 at low pHER23
signals. The key indicator of the synergistic effect of D1 and D2
is a change in the curvature of the response curve from convex to
concave at low pHER23 signal (0.1–0.3). We assume that modifi-
cation of the response curve defines the synergistic effect of HER2
and PI3K inhibitor combination (D1 and D2). Below, we show
that this effect corresponds to a significant decrease of the IC50
of pertuzumab in the presence of LY294002 (see Modification of
the Dose Response and its Sensitivity by Drug Combination in the
Presence of Mutations).
The additional benefit of this transformation of the response
curve is an insensitivity of the modified response (smooth sig-
moidal shape) to oncogenic mutations in the PI3K/PTEN/AKT
pathway at low pHER23 signals. To show the acquired robustness
of the network in the face of these mutations, we calculated the
response, RAKT= pAKT(pHER23, PAKT), at 50% PTEN loss and
AKT overexpression in the presence of 3µM LY294002 (green lines
in Figures 3A,C). As can be seen, PTEN loss and AKT overexpres-
sion did not change significantly the inhibited signal pAKT in the
range of inhibited input signal, pHER23< 0.3 (compare state d
and e in Figure 3A and points on lines 3 and 4 at pHER23= 0.1 in
Figure 3C, respectively). Thus, in contrast to our results on resis-
tance to 2C4 induced by PTEN loss and AKT overexpression, these
abnormalities in the context of PI3K inhibition did not result in
resistance to HER2 inhibition by 2C4. Note that the advantages
of that drug combination vanish at higher signals pHER23> 0.4
where mutations and protein overexpression significantly increase
pAKT signal (see lines 6 and 7 in Figure 3A and lines 3 and 4
in Figure 3C). Therefore, the response is more robust than an
unmodified hyperbolic one with respect to the activation of muta-
tions in the PI3K/PTEN/AKT pathway at inhibited pHER23 signal
(pHER23< 0.3).
This advantage of a modified smooth sigmoidal response curve
was confirmed by the calculation of sensitivities, SAKT and SAKT,p,
carried out in the presence of PI3K inhibitor (columns 5–8 in
Figure 4). As can be seen, at this modification, 90% inhibition of
pHER23 by pertuzumab causes a decrease in sensitivities, SAKT
and SAKT,p, in contrast to their increase at the pertuzumab treat-
ment alone (compare columns 2 and 6 in Figure 4). A decrease in
sensitivity SAKT at low pHER23 concentrations (row 1 in column
6 in Figure 4) confers robustness of 90% pAKT inhibition in a
wider range of inhibited pHER23 signal (up to 0.3; see lines 4–6
in Figure 3A and lines 3 and 4 in Figure 3C) than in the case of
hyperbolic response in the absence of the second drug. A slight
decrease in SAKT,p in turn leads to less sensitivity to oncogenic
mutations in the PI3K/PTEN/AKT pathway and suppression of
drug resistance in contrast to the case of pertuzumab treatment
alone. As can been seen from the I/O response curve, the robust
inhibition of pAKT at low pHER23 signal is independent of the
oncogenic mutations (mainly 50% PTEN loss and AKT overex-
pression) (compare points d and e in Figure 3A and points on
lines 3 and 4 in Figure 3C at pHER23= 0.1). Note this insensi-
tivity to mutations at this drug combination vanishes at higher
input signals pHER23> 0.4, where mutations and protein overex-
pression significantly increase pAKT signal (see, e.g., pAKT values
at pHER23= 0.6 on lines 6 and 7 in Figure 3A and lines 3 and
4 in Figure 3C). Thus, the combination of HER2 inhibitor with
PI3K inhibition endows the DSP with robustness against acti-
vation mutations in PI3K/PTEN/AKT pathway only at inhibited
pHER23 signal in the range up to pHER23= 0.3.
Note that in the model, drug D2 causes an increase in the sen-
sitivity SAKT,p to the protein parameters in comparison with the
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unperturbed SN that can sensitize the DSP to compensatory muta-
tions (see columns 1 and 5 in Figure 4). This discrepancy may be
due to the fact that in the calculation we compared the sensi-
tivity at inhibited (pHER23= 0.1) and saturated (pHER23= 1)
pHER23 signals (points d and a in Figure 3A, respectively). Here
we assumed that the activation growth factor signal (1 nM HRG)
is saturated (point a in Figure 3A). However, if we assume ligand
concentration to be lower than the saturation level (e.g., 0.6–0.8)
(51) and compare the sensitivities at inhibited and this pHER23
signal, we find that drug D2 does not change the sensitivity in
comparison with the unperturbed DSP (data not shown).
MODIFICATION OF THE DOSE RESPONSE AND ITS SENSITIVITY BY
DRUG COMBINATION IN THE PRESENCE OF MUTATIONS
To show how the modifications of I/O response of the AKT
subsystem, RAKT, effect on the dose dependence of the whole
ErbB/PI3K/PTEN/AKT network for drug D1, we calculated pAKT
and SAKT,p dose dependencies for pertuzumab at different pertur-
bations of the PI3K/PTEN/AKT subsystem discussed above (see
solid and dashed lines in Figure 5, respectively). Specifically, we
calculated sensitivity SAKT,k31 to the rate constant of the reaction
of PI3K binding with PIP2, k31 (see Figure 2 and model descrip-
tion in Supplementary Information). The calculation for other
parameters p was shown to effect the same results (as guaranteed
by the general behavior of SAKT,p for all p, according to the dis-
cussion of Eq. 5). In the case of an unperturbed DSP, sensitivity
SAKT,k31 increases by approximately 20 times (relative to its level
in the absence of pertuzumab) and has a peak at 80% inhibition of
pAKT (IC80 for pertuzumab) (see black circle and square on the
dashed and solid black lines at 100 nM pertuzumab in Figure 5,
respectively). Key features of the dose dependence SAKT,k31 calcu-
lated with the unperturbed PI3K/AKT module are the presence
of maximum in the range of IC80, a non-zero limit at high drug
concentrations, and a limiting value at low drug concentration,
which corresponds to the sensitivity of the signaling system in the
absence of the drug (see heatmap in Figure 4). The detailed analy-
sis of these features is given in Supplementary Information (see
Figures S1 and S2 in Supplementary Material).
The calculation of the pAKT dose dependencies for per-
tuzumab in the presence of PI3K inhibitor showed the shift of
the dose dependence curve to lower drug concentrations and
a decrease of IC50 for pertuzumab from 30 nM to 1 nM at an
increase in LY294002 concentration up to 3µM (see solid blue
line in Figure 5 and Figure S2 in Supplementary Material). In
contrast to dose dependence, calculation of relative sensitivity
SAKT,k31 revealed a complex behavior that only moves to low
pertuzumab concentrations at increasing LY294002 concentra-
tion: the maximum near IC80 disappears and sensitivity behavior
becomes almost monotonically decreasing with a slight minimum
(see Figure S2A in Supplementary Material). We assume that a
shape change of SAKT,k31 at the shift of the dose dependence is
the manifestation of transformation of the DSP response curve
(Figure 3A). Sensitivity SAKT,k31 at 3µM LY294002 does not have
maximum at IC80 and decreases from its initial value at low 2C4
concentration to approximately its limit value at high pertuzumab
concentration (see blue circle and square on the dashed and solid
blue lines, respectively at 6 nM pertuzumab in Figure 5). This dose
dependence corresponds to the modified response curve (line 6
in Figure 3A). We predict a significant decrease of IC50 for per-
tuzumab in the presence of 3µM LY294002 due to the synergistic
combination of these two drugs and explain this effect by modifi-
cation of the response of PI3K/PTEN/AKT pathway at low input
signals (line 6 in Figure 3A).
Calculation of absolute sensitivity,SAKT,k31 (Eq. S2.1 in Supple-
mentary Material), showed that it possesses similar features except
for a zero limiting value at high drug concentration (see Figure
S2B in Supplementary Material). Similarly, at 3µM LY294002,
absolute sensitivity loses its maximum in the range of IC80 and
FIGURE 5 |The dose dependences of pAKT inhibition (solid lines) and sensitivity SAKT,k31(2C4,p) of the PI3K/PTEN/AKT network to the rate constant of
the reaction of PI3K binding with PIP2, k 31 (dash lines) at different drug combinations. The dose dependencies of inhibition and sensitivity on pertuzumab
concentration (black lines), at 50% PTEN loss (red lines), at 3µM LY294002 (blue lines), at 50% PTEN loss and 3µM LY294002 (green lines).
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monotonically decreases when drug concentration increases. We
consider this transformation of sensitivity behavior as the results
of modification of the DSP dose response from hyperbolic to
smooth sigmoid shape (Figure 3). This transformation, and the
range of second drug concentration where it occurs, can be used in
optimization of drug composition to inhibit signaling, so avoiding
a significant increase in sensitivity of the SNs to mutations. Below
we consider one such optimization.
Transformation of the response of the DSP module leads to
pAKT inhibition by two drugs to exceed 80% in the wide range
of LY294002 concentrations (0.3–3µM) at a significantly lower
concentration of pertuzumab (6 nM) in comparison with pAKT
inhibition by pertuzumab alone, 100 nM (see Figure 5; Figure
S2 in Supplementary Material). This allows optimization of drug
concentrations with respect to both inhibition of pAKT signal and
sensitivity of the SN to mutations. Since these two characteristics
are interlinked and change correlatively in the same region of the
response curve (Figure 3A) and dose dependence (Figure 5), the
problem of trade-off between them arises. It is possible to disen-
tangle inhibition and sensitivity characteristics from each other by
optimal manipulation of two drugs in the concentration range dis-
cussed above. One can establish two optimized conditions of drug
combination action with high inhibition and low sensitivity. The
first optimum condition is to decrease 2C4 concentration to main-
tain 80% inhibition of pAKT (IC80= 6 nM) with low sensitivity at
2–3µM LY294002 (see blue square and circle on solid and dashed
blue lines respectively in Figure 5 and lines 5 and 6 in Figure S2 in
Supplementary Material). The second optimum is full inhibition
of pAKT with 100 nM pertuzumab and a minimal increase (six
times) of sensitivity at 3µM LY294002 (see large blue square and
circle on solid and dashed blue lines respectively in Figure 5).
To demonstrate the sensitivity to resistance transition in
response to HER2 inhibition at PTEN loss, we calculated the dose
dependences of pAKT and SAKT,p at 50% PTEN loss (see red solid
and dashed lines in Figure 5 and corresponding I/O response of
the pAKT, line 2 in Figure 3A). PTEN loss leads to a 10-fold shift
of pAKT dependence to a higher pertuzumab concentration, so
causing resistance to HER2 inhibition in the range of physiolog-
ical pertuzumab concentration (100 nM). In this region of drug
concentration, both inhibition of pAKT and sensitivity SAKT,p are
approximately zero (see red square and circle on solid and dashed
red lines in Figure 5, respectively). Sensitivity to HER2 inhibition
is restored through modification of the network by PI3K inhibitor,
LY294002. This modification causes approximately full inhibition
of pAKT (green square on green solid line in Figure 5) while sen-
sitivity SAKT,p (green circle on green dashed line in Figure 5) is at
approximately the same level as for normal PTEN concentration.
Joint analysis of the I/O response of the PI3K/PTEN/AKT
pathway and pAKT dose dependence for pertuzumab (drug D1)
revealed a trade-off between inhibition and sensitivity, which can
be formulated as follows. If the concentration of drug D1 is high
(low pHER23 signal), pAKT inhibition is strong and sensitivity to
protein parameters is low: this is of a benefit with respect to sig-
nal inhibition and suppression of compensatory mutations. If the
concentration of D1 is low (high pHER23 signal), pAKT concen-
tration increases while sensitivity decreases, which gives advan-
tages with respect to mutation suppression but leads to a decrease
in inhibition effect of the drug,D1. If the concentration of drugD1
is in the region of its IC50, sensitivity increases which affords the
use of the second drug more effectively (drug-sensitizing effect),
and a disadvantage with respect to increasing sensitivity of the SN
to compensation mutations. This analysis showed the inhibition-
sensitivity trade-off decision can be optimized by customizing
the I/O response of the SN through manipulation of the con-
centrations of the two drugs. Optimization of drug concentration
allows the separation of the regions with high inhibition and high
sensitivity, which overlap each other in single drug treatment.
DISCUSSION
We have shown that the sensitivity of the SN to drug action is
attended by an increase in sensitivity SDSP,p of the DSP to the
kinetic parameters and expression levels of the proteins involved
in this pathway. As a result, the DSP is sensitized by drug action
and may be more fragile with respect to mutations, which change
protein kinetic properties (catalytic or/and dissociation constants)
and their expression level (overexpression or suppression of gene
expression). In particular, an increasing sensitivity may result in an
adverse effect of inhibitor action since a high sensitivity endows the
SN with fragility with respect to mutations that can compensate
for the intended inhibitor effect by restoring a high output signal
as well as initial low sensitivity of the SN to external perturbations.
It follows that increasing SN sensitivity can be one of the causes
of resistance potential to drug action. We suggest that this effect
should be taken into account at drug target validation, and the
drug resistance potential linked with this sensitizing effect should
be evaluated in drug combination co-development. We present
a method to design drug combination strategies that modify the
I/O response of the SN to minimize any drug-sensitizing effect,
enhance robustness of drug inhibition effect, and improve drug
resistance potential by vertically targeting the SN.
The method is based on the modularity approach to analyz-
ing the efficacy of combination therapy developed by Fitzgerald
et al. (52). According to this approach, we divide the signaling sys-
tem into up- and down-stream pathways, which are the targets of
the first and second drugs, respectively (see scheme in Figure 1).
In this work, we focused on the I/O response characteristics of
the down-stream pathways, DSP, which is a signal transduction
module in the whole signaling pathway. As shown in Ref. (52),
the effect of drug combination significantly depends on the I/O
response properties of the receptor systems, and mainly receptor
expression level, that shifts the IC50 concentration of drug, D1.
To exclude the effects determined by the I/O response properties
of the receptor system, we considered only the output signal of
the USP which is varied from zero to a saturated level. In this
modularity approach, the effect of drug D1 defines only the input
signal for the I/O response curve of the DSP (see Figures 1 and
3A). We expanded this approach developed by Fitzgerald et al.
(52) to investigate the modification of the I/O response of the
down-stream pathways as a result of external and internal per-
turbations such as inhibition of signaling proteins and protein
mutations. The analysis of the responsiveness of the whole sys-
tem to the first drug was shown to depend significantly on the
I/O response characteristic of the down-stream signaling module.
We suggest that the response curve, RDSP, can be considered as
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a biomarker (characteristic signature) of a particular cancer sig-
naling pathways (e.g., MAPK, PI3K/AKT, Wnt, and others (53)
in specific cancer cell lines. To illustrate this, we have extracted
the I/O response RDSP of the PI3K/PTEN/AKT and MAPK path-
ways for different cancer cell lines using experimental data on the
dose dependence of receptor activation (EGFR and PDGFR) and
output signal (pAKT and pERK) on ligand concentrations (EGF
and PDGF) (49, 54, 55). The characteristic I/O response curves
obtained for different activating input signals in various cell lines
are shown in Figure 6. The experimental data on I/O responses
were fitted by the Hill function with a Hill constant, n, which char-
acterizes that response as switch-like (higher n) or more graded
(lower n). As shown, AKT responses are more varied compared
with the more conserved set of ERK responses that are typically
switch-like (n= 2.65–12.8). pAKT responses range from switch-
like for HBL and AU565 cells (Figures 6A,B) to graded hyperbolic
for T47 and PE04 cells (Figures 6C,E,F) and smooth sigmoidal
for MCF7 cells (Figure 6D) responses. We assume that such vari-
ety in the responses of the PI3K/PTEN/AKT pathway results from
a variation in the internal parameters of the networks caused by
mutations and different expression levels of signaling proteins.
We suggest that I/O responses can be considered as a biomarker of
mutation and protein expression status of specific cancer cells.
The in silico analysis of the I/O response of the
PI3K/PTEN/AKT pathway confirmed that the SN can possess a
smooth hyperbolic response, which corresponds to the sensitivity
mode in signal transduction, and this response can be transformed
into a switch-like response by changing protein parameters, which
corresponds to activating mutations of the proteins involved
(PTEN, PI3K, and AKT). This transformation relates to the tran-
sition from sensitivity to resistance of the SN to drug inhibiting
receptor signals (32). Joint analysis of the I/O response of the
PI3K/PTEN/AKT pathway and its sensitivity showed that these
two key characteristics of the cellular SN are interconnected and
they both significantly depend on the protein parameters and
their expression levels. We observed from in silico experiments
that perturbations of protein parameters corresponding either to
50% decreases in PTEN concentration (PTEN loss), PI3K acti-
vation mutation, or AKT overexpression significantly changes in
the I/O response of the PI3K/PTEN/AKT pathway and its sen-
sitivity. The transformation of the I/O response from smooth
hyperbolic to switch-like at PTEN loss significantly endows the
SN with hypersensitivity (56) that is assumed to be typical for the
signaling cascade in cells at decreasing phosphatase activity (38).
The steep switch response observed at PTEN loss is assumed to
be due to a post-translational regulation of PTEN activity by its
phosphorylation leading to the additional loss of PTEN activity
(31, 48) considered in our model.
We showed that PTEN loss, or PIK3CA activation muta-
tion, AKT and PI3K overexpression (40) decreased sensitivity
SAKT,p by four to six orders of magnitude for all protein para-
meters and this corresponds to the transformation of the I/O
response from smooth hyperbolic to switch-like. At this mutation,
the PI3K/PTEN/AKT pathway acquires insensitivity to further
FIGURE 6 | Input/output responses of PI3K/AKT and MAPK pathways to
the activation of growth factor receptors in different cells. The
dependences of pAKT and pERK on the activation level of ErbB1 receptors in
HBL100 (A), AU565 (B), T47 (C) cells; on the level of HER2 receptors in MCF7
(D) and PE04 (E) cells; and platelet-derived growth factor receptor (PDGF) in
NIH 3T3 fibroblasts (F). Data on I/O response were extracted from
experimental dose dependences [(A–C) (49), (D) (54), and (F) (55)] and
normalized at maximal values of input/output signals. pAKT, pERK dose
dependencies for PE04 cells (E) are theoretical data (40) (black lines).
Experimental data were fitted by Hill function: y = xn/(xn +Kn) with Hill
constant, n, and half-maximum constant, K, which are given in Figures. Hill
function is depicted by red lines for pAKT and blue lines for pERK.
Experimental data were kindly allowed to be used by PK Sorger (A–C),
M Hatakeyama (D), and JM Haugh (E).
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perturbation of the SN: it becomes robust in the face of both
external perturbations (inhibition of input signal) and internal
aberrations (mutations). PTEN loss leads to resistance to drug
action (resistance to HER2 inhibition) and causes robust activa-
tion of the AKT output signal (57). Note that the observed decrease
in sensitivity of the SN at either PTEN loss or PI3K aberration sug-
gests that PTEN loss and PIK3CA mutation are mutually exclusive.
Clinical study of oncogenic mutations in the PI3K/PTEN/AKT
pathway reported both the data on mutually exclusive of PTEN
loss and PIK3CA mutation in human breast (58) and gastric (59)
carcinomas and frequently concordant in breast cancer (43, 44). As
both mutations activate AKT and each decreases sensitivity of the
DSP to another mutation, our finding suggests either redundancy
in mutations, the need for two alterations in the single module to
activate AKT, or that PTEN loss and PIK3CA mutation contribute
differently to carcinogenesis (60).
Combining analysis of the I/O response with SA, we showed
that a hyperbolic response in sensitivity mode is robust at high
input (saturated receptor signals) and loses its robustness against
activation mutations of the proteins at low pHER23 signals.
Importantly, the I/O response can be modified through drug com-
bination action, here through customization of the I/O response
of the DSP by drug D2 to reach high robustness of the inhibition
response to drug D1 against oncogenic protein mutations in the
pathway, leading to the transformation of a hyperbolic response
to a graded sigmoidal response curve (see blue lines in Figure 3A).
The first benefit of that modification is an effective inhibition of
output signal, pAKT. The most pronounced inhibition effect of
the second drug is at low pHER23 region (0–0.2), where the sen-
sitizing effect by the first drug, pertuzumab, is at a maximum. We
exploit a synergistic interaction between these two drugs, specif-
ically the sensitizing effect of one drug on the action of another.
A second benefit of that modification is a decrease in the sensi-
tivity of this response in the range of low pHER23 signal (0–0.2)
(see blue lines in Figure 3A). We hypothesized that the mod-
ified response is more robust against oncogenic mutation than
the hyperbolic type of the response. To check this, we carried
out robustness screening of this response with respect to the fol-
lowing aberrations in the PI3K/PTEN/AKT pathway: PTEN loss,
activation mutation of PI3K, and overexpression of AKT. In all
these cases we observed effective inhibition of pAKT and so a
high degree of robustness in the modified response to common
oncogenic mutations in the PI3K/PTEN/AKT pathway (see green
lines in Figures 3A,C). We showed that a hyperbolic response is
more adapted to signal discrimination and signal transaction while
a modified graded sigmoidal response close to linear response
is more adapted to therapeutic inhibition of signaling pathway
activated by oncogenic mutations.
Note, a similar transformation from hyperbole to switch-
like response was observed in silico and in vitro experiments in
Raf/MEK/ERK pathway as a result of deletion of negative feed-
backs from ppERK to Son of Sevenless protein (SOS) and Raf
(26). This finding and other theoretical and experimental studies
show that multiple feedback and gene regulation can significantly
control drug efficacy (4, 5, 52). An extension of the modularity
approach used in our work should be performed to explore the
consequences of feedback and gene regulation networks, which
control the robustness of SNs in normal and malignant condi-
tions (61, 62). For example, to develop more reliable model of
SN response to drug combination, it is necessary to take into
account the negative feedback in the PI3K/PTEN/AKT pathway
which includes phosphorylation (inactivation) of GSK3β by pAKT
which phosphorylates (inactivates) PTEN, and therefore increases
AKT phosphorylation (31).
As discussed in the Section “Introduction,” many experiments
and clinical trials confirm the suppression of drug resistance
and the robustness response of drug combinations acting on
the vertical signaling pathways in different cancers. For exam-
ple, complementary inhibition of the vertical targets in the
PI3K/PTEN/AKT/mTOR pathway restores the inhibition effect of
trastuzumab and pertuzumab (15, 17). Moreover, the experimen-
tal study of the combination of PI3K inhibition (GDC-0941) with
HER2 inhibitors (trastuzumab, pertuzumab) showed that the high
efficacy of this combination therapy is a general effect for different
breast cancer cell lines despite the fact that different cell lines have
different susceptibilities/resistance to each drug separately (42).
Our in silico experiments indicate that anti-cancer response
robustness to drug action emerges due to a smooth sigmoid
response of the SN when modified by drug combination. Experi-
mentally, the robustness of the modified response to a change in
expression level of signaling proteins can be measured in RNA
interference (RNAi) screening with respect to repression of pro-
tein expression. RNAi screening has been applied successfully to
a study of resistance mechanisms and development of effective
combination therapy by determining drug targets (60, 63), and
allows estimation of the robustness of the therapeutic response to
the perturbations in expression of the proteins (isomers or cat-
alytic/regulatory protein subunits) surrounding drug targets in a
SN (both vertical and horizontal targeted pathways). Robustness
screening with respect to overexpression of the proteins surround-
ing targeted proteins can be measured using isogenic cell clones
customized to genomic status involved in screening (64). Most
critical experimental validations are assumed to be carried out
with heterogeneous tumor samples. Here we suggest that design-
ing into a combination therapy regime, an unchanged landscape
of sensitivity across a mutation spectrum, such as that shown in
heatmap in Figure 4 (columns 5, 6, and 8), may slow down the evo-
lution of subpopulations of cancer cells under a selection pressure
of drug therapy and suppresses the development of drug-resistant
clones (28, 65). Further, effecting this slowing down in resistance
evolution may require a longer-term engineered drug combina-
tion regime that accounts for a drift in cell signaling behavior over
many cellular generations.
The method of investigation of the I/O response of the SN mod-
ules developed here can be considered as a supplementary tool for
the analysis of the dose dependence for drug D1 and the mech-
anism of IC50 changes at oncogenic mutations and combination
therapy. To show the link between response dynamics properties
of the PI3K/PTEN/AKT pathway and the dose response of the
whole SN, we calculated the dose dependence of pAKT on con-
centration of pertuzumab (drug D1): RSN=Cout (C in,D, PSN, t ),
and showed how the modification of the DSP response by muta-
tions and drugs changes IC50 for pertuzumab (Figure 5). In the
calculation, we observed a decrease of IC50 for pertuzumab in the
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presence of PI3K inhibitor, LY294002, suggesting lower concentra-
tions to be effective. These results supplement the analysis of the
drug-induced shift in dose dependence and the synergetic effect of
two drugs targeting vertical pathways discussed by Fitzgerald et al.
(52). Additionally, we showed that drug-induced sensitivity to the
second drug modify both response curve and dose dependence for
the first drug that significantly enhances synergetic effect of two
drugs in combination.
We showed that the sensitivity of the DSP without customiza-
tion increases significantly in the range of IC80 of pertuzumab
(see solid and dashed black lines in Figure 5). The simplest way to
reach the goal of high inhibition and low sensitivity is to increase
the drug concentration and go far beyond the range of maximal
sensitivity (>1µM pertuzumab, Figure 5). In practice, this is often
not a realistic solution for toxicity reasons, although there is evi-
dence that drug concentrations that are twice the IC50 can suppress
acquired resistance due to mutations following drug therapy (29).
A more realistic approach is to customize the network response to
inhibition through combination therapy, manipulating the inhi-
bition and sensitivity dose dependencies through the action of the
second drug, which modifies the I/O response of the DSP. Addi-
tionally, our calculation showed that a significantly lower IC50 for
pertuzumab in combination with the PI3K inhibitor can be a basis
for decreasing a dose of drug D1 to reduce its toxicity.
We applied the method to two well-known targets and drugs
and investigated the mechanism of their effectiveness. We demon-
strated that the drug-induced sensitivity of the DSP to changes in
protein parameters and their expression levels has the potential
to sensitize this pathway to mutations that compensate for drug
action, i.e., low output signal at inhibited input signal. Moreover,
such mutations can effect a decrease in sensitivity of the DSP to
further external and internal perturbations leading to an increase
in DSP robustness. It is thus possible that drug action may sig-
nificantly perturb DSP functioning, stimulating the activation of
compensatory response mechanisms in the cell.
We then demonstrated a method of minimizing the drug-
sensitizing effect while maintaining the intended effect of drug
action by customizing the I/O response of the DSP response.
The goal of this customization was to reach a high inhibition of
input signal without sensitizing the SN to mutations leading to
an increased potential for resistance, specifically PTEN loss and
AKT overexpression. Our focus was the modification of the I/O
response of the PI3K/PTEN/AKT pathway to inhibition of pHER2
by pertuzumab.
These results suggest that the I/O response of signaling mod-
ules can be used as biomarker to select advantaged drug targets
for mono- and combination therapy. To illustrate this concept,
we considered different strategies of drug selection depending on
the response of the PI3K/PTEN/AKT signaling module of the dif-
ferent cells represented in Figure 6. We assume that in the case of
switch-like response with low threshold of activation (low parame-
ter K ) such as represented in Figure 6A (HBL cells) and Figure 6B
(AU565 cells), a rational strategy is to use drug combination in
which one drug targets the DSP and modifies the response curve
to more graded or sigmoid form while another drug in combina-
tion inhibits input and output signals according to that modified
response curve. In the case of responses of smooth hyperbolic
type like represented in Figure 6C (T47), Figure 6E (PE04), and
Figure 6F (NIH 3T3), the drug targeting USP effectively inhibits
pAKT in the 80–90% range of inhibited receptor signal but sensi-
tizes down-stream module to compensation mutations. To avoid
the latter effect, we suggest modifying the response of the down-
stream module to a smooth sigmoid curve by a second drug
targeting the DSP. The I/O smooth sigmoid response of the type
given in Figure 6D (MCF7) is assumed to endow the signaling
module with high sensitivity to the drug inhibiting its input sig-
nal and low sensitivity to compensatory mutations. In this case,
inhibition of the USP by one drug is effective with respect to both
signal inhibition and sensitivity suppression. The use of the second
drug targeting down-stream pathway is redundant from the view-
point of the response modification and toxicity. These analyses
indicate the strategy of drug–diagnostic co-development (2, 66)
when drug therapies (mono- or combination) are selected based
on the integrative biomarker corresponding to the I/O response of
signaling modules. Stratification of patients according to different
I/O response curves can help identify patients who are most likely
to benefit from selected therapy. Constant monitoring of the trans-
formation of the I/O response curve during treatment can indicate
at compensatory gene regulation (12, 45, 67, 68) and acquired
mutations as a result of the selected therapy and so can serve
as a guide for changing therapeutic regime. The obtained results
showed that it is desirable to introduce an additional characteristic
of drugs to support this strategy – drug-induced sensitivity of the
SN or resistance potential of drugs, which significantly depends
on the I/O response of targeted SN.
The joint analysis, the I/O response of the PI3K/PTEN/AKT
pathway, and pAKT dose response for pertuzumab revealed the
challenge of the trade-off between high sensitivity to drug action
and oncogenic mutations. The proposed method of modifica-
tion of the I/O response of the PI3K/PTEN/AKT pathway and
manipulating separately by the inhibition and sensitivity dose
dependencies through action of a second drug resolved this prob-
lem partially. Despite PI3K inhibition causing the loss of relative
sensitivity at different perturbations (pHER2 inhibition and the
different mutations in PI3K/PTEN/AKT pathway), it increased the
overall level of sensitivity of the DSP to protein parameters that
is assumed to sensitize the SN to the compensation mutations
(compare columns 1 and 5 in Figure 4). To further optimize this
trade-off at the combination design stage, we propose that other
means of customizing the I/O response to improve drug resis-
tance potential are needed, e.g., by using the methods and results
of synthetic biology in signaling pathway engineering to customize
their I/O responses (69–71). For example, using some modulators
it is possible to alter/reshape dose dependence from a graded to a
sharply sensitive, switch-like response and a time dependence from
sustained to pulse or delayed responses in MAPK pathway signal-
ing (71). It has been shown that modification of cellular response
obtained by genetic engineering can also be reached through
drug action. For example, cellular responses were engineered by
dynamic rewiring of SN topology (22, 72) and controlling nega-
tive feedback circuits in SN by drug combination (26). Ultimately
the application of this arsenal of engineering methods in net-
work and synthetic biology, underpinned by integrative systems
biology, can be a powerful tool for adaptation of signaling response
to effective combination therapy and rational drug combinations
co-development.
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